2B70:XETRA:XETRA-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 6.382

Change

0.00 (0.00)%

Market Cap

USD 0.52B

Volume

0.05M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-15 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.17 (+0.33%)

USD 426.26B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.05 (+0.28%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.13 (+0.47%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.07 (+0.25%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.12 (-0.47%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

+0.03 (+0.07%)

USD 104.42B
8R80:XETRA Amundi Index Solutions - Amund..

+0.02 (+0.01%)

USD 104.42B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.18 (+0.34%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.60 (+0.59%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+3.00 (+0.52%)

USD 80.38B

ETFs Containing 2B70:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.76% 71% C- 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.76% 70% C- 69% C-
Trailing 12 Months  
Capital Gain 15.76% 70% C- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.76% 69% C- 69% C-
Trailing 5 Years  
Capital Gain 49.97% 71% C- 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.97% 71% C- 69% C-
Average Annual (5 Year Horizon)  
Capital Gain 5.37% 52% F 51% F
Dividend Return 5.37% 51% F 50% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 13.48% 45% F 55% F
Risk Adjusted Return 39.81% 45% F 48% F
Market Capitalization 0.52B 67% D+ 58% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.